IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 /PRNewswire/ -- IASO Biotechnology ('IASO Bio'), a commercial-stage biopharmaceutical company focused on the discovery, development, ...
B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of ...
In early December 2025, Andean Silver Limited requested a trading halt on its shares pending a material update on its capital raising plans, following recent investor presentations in Sydney and ...
Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...
If you've just signed up for Apple TV and aren't sure which show to binge, here are 25 original series that we believe make ...
The advent of the “action roguelike” was a major leap forward, opening up the possibilities of what developers could do […] ...
Incyte Corporation's stock is attracting positive attention following significant progress in its oncology development ...
There’s something magical about a restaurant so special that people willingly add miles to their odometers just for a meal, and Indian Pueblo Kitchen in Albuquerque has earned that rare distinction ...
CNW/ - Gold Royalty Corp. ("Gold Royalty" or the "Company") (NYSE American: GROY) is pleased to announce that it has entered ...
Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, today announces the appointment of Francis Van Parys as Chief Executive ...
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback